Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03840694
Other study ID # Pro00101055
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 10, 2019
Est. completion date May 13, 2021

Study information

Verified date May 2021
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to find out how smoking affects the way the brain responds to pleasure and how this impacts smokers' behavior. Participants will complete three sessions. The first session will be a screening and training visit to determine final eligibility. Eligible participants will work with a researcher to develop brief scripts about times when they smoke and do other activities. Next, participants will attend two magnetic resonance imaging (MRI) scans - one after abstaining from smoking for 24 hours and the other after smoking as usual. After the second MRI, participants will answer questions on their phone every day for two weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 21
Est. completion date May 13, 2021
Est. primary completion date May 13, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 55 Years
Eligibility Inclusion Criteria: - Generally healthy - Right-handed - Smoke >= 10 cigarettes per day - Smoking regularly for >= 1 year - Carbon Monoxide (CO) > 8 at screening (or urinary cotinine > 100) - Own a compatible smartphone - Able to read and understand English - Able to identify at least 4 pleasurable activities they do not do concurrently with smoking or associate with smoking Exclusion Criteria: - Regular use of "roll your own" cigarettes - Planning to quit smoking within the next 60 days - Current or planned smoking cessation treatment - Regular use of smokeless tobacco or other nicotine products - Expired CO > 80 parts per million - Breath alcohol > .000 at screening (re-attempts are allowed) - Positive toxicology screen for exclusionary drugs - Use of exclusionary medications - Significant medical problems - Currently breastfeeding, pregnant, or planning to become pregnant - Enrollment in another study utilizing Spectrum cigarettes within the last 3 months - Irregular slee-wake cycles (e.g. swing-shift work, unusual sleep patterns)

Study Design


Intervention

Other:
Smoking Abstinence
Participants will abstain from smoking for 24 hours.
Ad Lib Smoking
Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.

Locations

Country Name City State
United States Duke University School of Medicine Durham North Carolina

Sponsors (4)

Lead Sponsor Collaborator
Duke University Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood Oxygen Level Dependent (BOLD) Activation BOLD activation in brain reward network regions Approximately 1-3 weeks
Primary Ecological Momentary Assessment (EMA) Pleasure Ratings Anticipated and actual pleasure ratings acquired each day during EMA portion of study. Individual items are based on the 12-item Tripartite Pleasure Inventory (TPI). Participants rate their anticipated pleasure for activities they expect to engage in each day using a 0 (No pleasure) to 4 (Extreme pleasure) scale in the morning. They will then rate their actual experienced pleasure for activities they actually did engage in the evening using the same scale. Scores are summed across items for a theoretical range of 0-48. 2-6 weeks
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Active, not recruiting NCT02643914 - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A
Active, not recruiting NCT02629679 - Sports, Education and Consumption of Substances in Adolescents N/A
Completed NCT02385227 - Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes N/A
Completed NCT02218281 - Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation N/A
Completed NCT01199380 - Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms Phase 2
Completed NCT00756704 - The Effectiveness of Smoking Cessation Guidelines in the Emergency Department N/A
Completed NCT00802919 - Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Phase 4
Completed NCT01692353 - Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers N/A
Completed NCT01081119 - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth Phase 2
Completed NCT00682474 - School Nurse-Delivered Smoking Cessation Intervention Phase 2/Phase 3
Completed NCT05520775 - Semaglutide for Alcohol Use Disorder Phase 2
Completed NCT03743532 - E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services N/A
Completed NCT06032793 - Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness. N/A
Terminated NCT03326128 - High Dose Bupropion for Smoking Cessation - Pilot Study Phase 2
Recruiting NCT03218670 - Your Health in On Click N/A
Completed NCT02538042 - Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue) N/A
Completed NCT02792426 - Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users Phase 1